SSGJ-707 in Advanced Non-Small Cell Lung Cancer

Exclusion Criteria

• •1. Presence of small cell carcinoma components in histological pathology.
• •2. Presence of EGFR-sensitive mutations or ALK fusion-positive NSCLC.
• •3. Known BRAF V600E mutation, MET exon 14 skipping mutation, NTRK fusion, RET fusion, or ROS1 fusion-positive NSCLC.
• •4. Presence of brainstem, leptomeningeal, spinal cord metastasis or compression.
• •5. Unresolved toxicity from prior anti-tumor treatment, defined as toxicity not returning to NCI CTCAE Version 5.0 Grade 0 or 1.
• •6. History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
• •7. History of immunodeficiency; positive for HIV antibodies;
• •8. Known active tuberculosis (TB);
• •9. Known history of severe allergy to any component of the investigational drug, or history of severe allergic reactions to chimeric or humanized antibodies.
• •10. Pregnant or breastfeeding women.
• •The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.